Understand the source comparison
Is AHK-Cu Safe Side Effects: Safety Comparison
The table below compares AHK-Cu to other copper peptides and research compounds in terms of documented adverse event profiles, regulatory status, and evidence quality. AHK-Cu Injection-site erythema (5–10% incidence in rodent models), no systemic toxicity at ≤
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares AHK-Cu to other copper peptides and research compounds in terms of documented adverse event profiles, regulatory status, and evidence quality.
- AHK-Cu
- Injection-site erythema (5–10% incidence in rodent models), no systemic toxicity at ≤10 mg/kg
- None. No peer-reviewed human trials as of 2026
- ~0.1–0.3 mg elemental copper per 5 mg dose
- Research-grade only, not FDA-approved
- Favorable preclinical safety profile but limited human data; low systemic risk based on mechanism
- GHK-Cu
- Transient injection-site reactions, no hepatic or renal toxicity in 28-day rodent study
- Small open-label dermatology trials (n=20–40) showing no serious adverse events
- ~0.15 mg per 5 mg dose
- Research-grade; compounded formulations available
- Better-documented than AHK-Cu; safety profile appears comparable
- BPC-157
- Minimal adverse events in animal studies; rare reports of transient nausea in human anecdotal use
- No Phase III trials; multiple Phase I/II trials underway
- N/A (no copper component)
- Research-grade only
- Extensively used in research community; low reported adverse event frequency
- Copper gluconate (oral supplement)
- GI upset (nausea, cramping) at doses >5 mg elemental copper
- Decades of use as dietary supplement; well-established safety data
- Variable (typically 1–2 mg per tablet)
- FDA-approved as dietary supplement
- Oral bioavailability lower than chelated peptides; known to cause GI side effects at high doses
- AHK-Cu's advantage over oral copper supplementation is targeted delivery—copper peptides demonstrate enhanced cellular uptake via peptide transporters and endocytosis, bypassing first-pass hepatic metabolism. This means lower doses achieve comparable tissue-level effects, reducing total copper load. The tradeoff: injectable administration introduces infection risk and requires sterile handling, which oral supplements do not.